Sector News

Novartis snaps up neuro partner Cadent for $210M upfront with promise of up to $560M more

December 20, 2020
Life sciences

Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Five years later, the Swiss pharma is helping itself to the rest of Cadent’s pipeline in a deal worth $210 million upfront but that could net the latter up to $770 million in total.

Novartis will acquire all of Cadent’s outstanding stock in exchange for the upfront fee and up to $560 million in milestone payments. The duo expects the deal to close in the first quarter of 2021.

Under the deal, Novartis will buy out the milestones and royalties for the depression asset, MIJ821, which it is testing in a phase 2 study. It also picks up CAD-9303, a treatment for schizophrenia, and CAD-1883, which is in development for movement disorders.

Cadent emerged from stealth in November 2018 with a new chief medical officer and $40 million to push three programs into phase 2. Its programs target ion channels by tuning them up and down like dimmer switches rather than switching a light on or off, said Michael Curtis, Ph.D., then Cadent’s CEO, in 2018.

As Novartis pushed its depression asset through the clinic, the progress of CAD-9303, Cadent’s schizophrenia program, compelled it to turn the partnership into an acquisition, said Gopi Shanker, interim co-head of neuroscience at Novartis Institutes for BioMedical Research.

CAD-9303 targets an ion channel called the N-methyl-D-aspartate (NMDA) receptor, which is underactive in patients with schizophrenia. Cadent—and, obviously, Novartis—believe targeting this receptor could fill a gap in schizophrenia treatment, namely tackling the cognitive deficits and so-called negative symptoms of the disorder.

The symptoms of schizophrenia are generally divided into the positive—where people experience hallucinations, delusions or any change in behavior or thought—and the negative—where people appear to withdraw, seem emotionless or do not feel pleasure.

“The standard of care right now uses antipsychotics to address the positive symptoms in schizophrenia,” Shanker said. But there aren’t any good options to control the negative symptoms.

“The negative symptoms and cognitive impairment in schizophrenia have been linked to suboptimal function of NMDA receptors. This is a class of receptor that is genetically and clinically validated in schizophrenia, but it’s been historically challenging to develop the right molecule to modulate these receptors optimally.”

The deal comes about six weeks after the Swiss pharma dropped $150 million to acquire Vedere Bio and its suite of preclinical gene therapies designed to restore vision. It promised another $130 million in milestone payments.

Novartis added the Vedere assets to a pared-down eye medicine business, having spun out its Alcon unit in March last year and shifted focus to a trio of new opportunities in ophthalmology. The first is brolucizumab, a treatment for wet age-related macular degeneration, and the second, coincidentally, is Luxturna, to which it gained ex-U.S. rights in 2018. The third is exploring digital solutions in eye care, with some potential M&A to come.

by Amirah Al Idrus

Source: fiercebiotech.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach